WO1999045982A2 - A catheter to be inserted into a blood vessel, and a method for detection of substances - Google Patents
A catheter to be inserted into a blood vessel, and a method for detection of substances Download PDFInfo
- Publication number
- WO1999045982A2 WO1999045982A2 PCT/SE1999/000259 SE9900259W WO9945982A2 WO 1999045982 A2 WO1999045982 A2 WO 1999045982A2 SE 9900259 W SE9900259 W SE 9900259W WO 9945982 A2 WO9945982 A2 WO 9945982A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microdialysis
- catheter
- channel
- catheter body
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14525—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis
- A61B5/14528—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis invasively
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/28—Apparatus therefor
Definitions
- the invention relates to a catheter, to be inserted into and guided by a blood vessel, comprising an elongate catheter body, having a distal end and a proximal end, and an outer essentially cylindrical surface, limiting a wall structure, enclosing at least two channels, and to a method for detection of substances in a heart. Further it relates to a method for detection of at least one substance indicating metabolic changes in a heart.
- the human heart represents a major organ with respect to morbidity and mortality among the population.
- myocardial infarction and coronary artery disease still represent major causes of death.
- Acute myocardial infarction was the primary cause of 25023 deaths during 1992 in Sweden (AFA, Arbetsmarknadens F ⁇ rsakrings Aktiebolag, "Hjartinfarkt och samhalle", 1995.).
- Microdialysis is used to monitor the interstitial fluid in various body organs with respect to local metabolic changes.
- a dialysis probe is disclosed, which is primarily used for insertion in biological tissues, for example brain tissue.
- the probe is located in the tissue through operation. It can also be inserted in a blood vessel or a tissue in the same manner as a canula and is then provided with a pointed, cutting edge. Consequently it is not suitable to be inserted into and guided by a blood vessel. Also the design of the dialysis chamber makes it unsuitable for insertion into and guidance by a blood vessel, since it is too fragile .
- a continuous, rapid and selective detection of metabolic disturbance of the heart during ischaemia would greatly enhance the possibilities of active intervention in the development of myocardial infarction with non-reversible damage of the heart in patients admitted to cardiac intensive care units as well as in patients undergoing cardiac surgery.
- a device is achieved, which can be used when measuring substances in blood, without the need of taking blood samples.
- a device is achieved, which has a short response time when used for measuring/monitoring substances in blood.
- the catheter can be used for taking samples from the coronary sinus and the right atrium of an adult.
- a guide wire can be used for facilitating the introduction of the catheter.
- a catheter which is detectable with X-rays, and correct position of the catheter can be ensured by means of X-ray detection.
- Fig. 1 is a partly broken diagrammatic view of a first embodiment of a catheter according to the invention
- Fig. 2 is a cross sectional view taken at II-II in Fig. 1,
- Fig. 3 is a cross sectional view taken at III-III in Fig. 1,
- Fig. 4 is a longitudinal section taken at IV-IV in Figure 2
- Fig. 5 is a partly broken diagrammatic view of a second embodiment of a catheter according to the invention.
- Fig. 6 is a cross sectional view taken at VI-VI in Fig. 5, and
- Fig. 7 is a longitudinal section taken at VII-VII in Fig. 5. DESCRIPTION OF PREFERRED EMBODIMENTS
- FIG. 1 is a partly broken diagrammatic view of a first embodiment of a catheter 1 according to the invention.
- the catheter comprises an elongate catheter body 2 having an essentially cylindrical outer surface, a distal end 21, and a proximal end 22, between which it preferably is continuous, except for the openings which will be explained below.
- the catheter body 2 is preferably made of radio opaque PVC or other suitable material, and its outer diameter is preferably in the range of 5- 7,5 Fr ( «1,5- 2,5 mm).
- the catheter body 2 includes a number of longitudinal channels.
- Two of the channels 23, 24 are designed for circulating dialysis solution, and at their proximal ends they are connectable to means 10 for circulating, monitoring or analyzing, and preferably collecting the dialysis solution.
- the channels 23, 24 are shown to have the same inner diameters. However, the channels can have different inner diameters, and their cross sections can have different shapes than the shown. In the case of different inner diameters, channel 24 preferably has the smaller, and dialysis solution flows from the means 10 through channel 24 and back through channel 23.
- the catheter body 2 has an opening 25, which is best seen in Figures 1 and 2.
- the form of the opening 25 in the outer surface of the catheter body 2 can for example be circular, oval or essentially rectangular.
- the length of the opening 25, in the longitudinal direction is preferably 10- 30 mm.
- the opening in the catheter body 2 can be formed by removing a part of its wall by cutting away a portion of the catheter body 2 in a wall region of channel 23, whereby a section of channel 23 is opened, and thus a space or chamber 26 is formed.
- the chamber 26 is provided with a wall formed by a microdialysis membrane 30, in order to provide a microdialysis chamber 26.
- the channel 26 is enlarged in this section by the removal of the wall part, as shown in the figures. A part of or the whole circumference to said region can be cut away to further enlarge the chamber 26 and thus enlarge the dialysis surface.
- channels 23 and 24 are connected by a channel or opening 27 between the chamber 26 and channel 24, so that dialysis solution can flow between the channels.
- the channel or opening 27 is preferably arranged so as to connect a distal portion of the chamber 26 and the channel 24, but other placements could also be possible.
- the channels 23 and 24 are plugged or sealed between channel 27 and the distal end of the catheter body 2, by means of a plug or a seal 28, 29, in order to prevent dialysis solution from entering channels 23, 24 beyond channel 27. Further, channels 23 and 24 are plugged or sealed at the distal end 21 of the catheter body 2.
- microdialysis membrane 30 having a socket-like shape, and surrounding a portion of the catheter body 2.
- the microdialysis membrane 30 is partly broken up, so that the opening 25 and the chamber 26 can be seen.
- the microdialysis membrane 30 can be slid on to the catheter body 2 over the distal end 21.
- the microdialysis membrane 30 is further bonded or fastened with a glue or adhesive, or by other suitable means to the catheter body 2, in order to prevent any liquid to enter or exit between the microdialysis membrane 30 and the catheter body 2 from or to the outside.
- the catheter body 2 can be provided with an annular recess, for receiving the microdialysis membrane 30, in said region surrounding the opening 25.
- a microdialysis membrane 30 of cuprophane, polycarbonate or PES molecular cut-off between 1- 200 kD
- the microdialysis membrane 30 may be surface heparinized.
- a guide wire channel 50 for receiving a guide wire 51, can be arranged in the catheter body 2.
- the distal end of the catheter body 2 is closed or sealed except for an opening 52.
- This opening 52 forms a continuation of the inner surface of the guide wire channel 50.
- the guide wire 51 is used during insertion of the catheter, to increase the stiffness of the catheter 1, and to make it possible to bend the catheter 1 into a desired curve, in order to facilitate its insertion.
- the guide wire 51 is removed, and a blood sample can be taken out at the proximal end of the catheter 1 through the opening 52 and the guide wire channel 50.
- the guide wire 51 is provided with a stop 53.
- the catheter body 2 can advantageously be manufactured from an extruded continuous profile body.
- the profile body is cut to a desired length, and the channels, except the guide wire channel, are sealed or plugged at their distal ends.
- the microdialysis chamber is formed by cutting, the channel between the channels (microdialysis chamber and channel) are formed, and the blind ends of the channels are sealed or plugged. Thereafter the catheter body 2 is provided with a microdialysis membrane, and connections or connection tubes at the proximal end.
- the distal portion of the catheter may be preformed into a desired curvature so that by torquing the catheter about its longitudinal axis, the catheter can be manipulated to the desired location.
- the catheter To provide sufficient control over the movement of the catheter, it is necessary that its structure is somewhat rigid. However, the catheter must not be so rigid as to prevent navigation of the catheter through blood vessels to arrive at the precise location where the microdialysis procedure will be performed. In addition it is necessary that the catheter is not so rigid as to cause damage to the blood vessels through which it is being passed.
- the catheter While it is important that the catheter not is so rigid as to cause injury to blood vessels, it is also important that there is sufficient rigidity in the catheter to accommodate torque control, i.e. the 'ability to transmit a twisting force along the length of the catheter. Sufficient torque control enables controlled manoeuvrability of the catheter by the application of a twisting force at the proximal end of the catheter that is transmitted along the catheter to its distal end.
- the preform is also advantageous in that, it helps the catheter to remain in the right position when once correctly located.
- FIG 5 a second embodiment of a catheter according to the invention is shown.
- This catheter includes a first microdialysis chamber 26, with associated channels 23,24, a first opening 25 and a first microdialysis membrane 30, as described in connection to the first embodiment according to figure 1.
- a second opening 45 is provided in the catheter body 2, located on the opposite side to the first opening 25.
- a second microdialysis chamber 46 with associated second microdialysis membrane 31, and channels 43, 44, is arranged in connection with the second opening 45, in the same manner as in the first embodiment.
- Channels 43, 44 are connected by means of a channel 47, preferably at the distal portion of the second microdialysis chamber, and the channels 43, 44 are preferably sealed or plugged 48, 49 to prevent dialysis solution to enter the portions of the channels between channel 47 and the distal end of the catheter body 2, in the same manner as in the first embodiment.
- the two channels 43, 44 are connected at their proximal ends to the same means 10, for circulating, monitoring or analyzing, and preferably collecting the dialysis solution, as the two channels 23, 24, or to separate means.
- Figure 6 is a cross sectional view taken at VI-VI in Fig. 5, showing a possible placement of the two channels 23, 24, the two channels 43,44, the guide wire 51, and the guide wire channel 50 inside the catheter body 2.
- the catheter is inserted with the help of the guide wire into a blood vessel of a patient, e. g. the jugular vein or the subclavian vein by Seldinger technique.
- the catheter is thereafter guided in the vein and advanced into the right atrium of the patient's heart and positioned into for example the coronary sinus, so that the first microdialysis chamber will be located in the coronary sinus.
- the achievement of the right position is facilitated.
- the correct position is ensured by blood sampling through the opening 52 and the guide wire channel 51, with measurement of oxygen saturation, or alternatively by X-ray or ultra sonic detection.
- the catheter with two microdialysis chambers the distance between the two chambers is selected so that the second chamber then will be located in the right atrium, so that microdialysis can be performed in both the coronary sinus and the right atrium. This distance is about 100- 120 mm for an adult.
- the openings in the catheter body 2 are located at substantially diametrically opposed sides of the catheter body 2 , so that it is possible to place the catheter in a position where the patients blood easily can pass and get in contact with the both microdialysis membranes.
- the catheter In order to use the Seldinger technique the catheter must have a suitable flexibility. This is achieved by selecting the thickness of the parts thereof with respect to the properties of the respective material. However, this is common knowledge for a person skilled in the art.
- the catheter 1 could be tunulated through the skin of the patient, and placed directly into the coronary sinus during cardiac operations.
- the insertion hole is sealed with a suture to enable removal of the catheter 1 through the skin during post operative monitoring.
- external means 10 include container for dialysis solution, container for collecting microdialysis solution that has passed a microdialysis chamber 26, 46, and pumps for circulating the microdialysis solution through the respective pair of channels 23, 24 and 43, 44. Further it includes means or apparatus for monitoring or analyzing the microdialysis solution having passed a microdialysis chamber.
- the concentration of substances having passed from the blood in the vein through a microdialysis membrane 30, 31 to the microdialysis solution in the microdialysis chamber 26 ,46 by microdialysis and transported to the monitoring or analyzing apparatus, can be measured.
- substances could be metabolic markers, such as ASAT, ALAT CK/CK-B, troponin-T and troponin-I, or substances such as lactate, pyruvate, glucos, glycerol, urea, aspartate, glutamate, myoglobin, hypoxanthines or peptides .
- the concentration of the monitored substances can be measured in e.g. both the coronary sinus and the right atrium.
- the measurement from the right atrium is then used as a reference value, when detecting changes in the coronary sinus.
- the values so obtained, with either of the two embodiments of a catheter can be used for detection of metabolic changes in a heart of a patient with myocardial ischaemia, as one of a number of indications of development of myocardial infarction. Other indications are received from ECG-monitoring and monitoring of hemodynamic changes, arrythmias and blood pressure changes.
- the concentration thereof is highest in the heart. Therefore, in order to achieve the most accurate and rapid response it is preferred to take the sample for measurements in the heart, preferably in the coronary sinus.
- Some of the substances to be detected and/or measured have a very short lifetime in the blood since they are absorbed and metabolized, e.g. by the red blood cells (erythrocytes) . It is therefore very advantageous to isolate these substances from the blood by the microdialysis process. In the microdialysis solution they will remain constant (i.e. not metabolized), which is advantageous for the measurement, especially when they can be isolated already in the heart.
- the samples to be analysed are obtained by microdialysis of blood in the coronary sinus, they can also be obtained by microdialysis of blood in other parts of the vascular system, e.g. in an artery.
- concentration of the substance (s) e.g. glutamate
- the blood from the myocardium will be mixed and diluted, in the blood stream, which leads to a lower concentration of the substances to be measured.
- the metabolism and absorption in the blood of some of the substances also cause a decreased concentration at a distance from the heart.
- the substances which can be obtained, monitored and/or measured (e.g. the concentration of) in an artery are the same as for the coronary sinus, i.e. at least one substance in a group consisting both of metabolic markers, such as ASAT, ALAT CK/CK- B, troponin-T and troponin-I, and substances such as lactate, pyruvate, glucos, glycerol, urea, aminoacids, myoglobin, purines and peptides .
- the substances can be continuously monitored when the microdialysis process is continuous, also when the samples are obtained from other parts of the vascular system.
- Myocardial ischemia i.e., quantitative deficiency of oxygenated blood delivered to the myocardial tissue produced by local obstruction to the arterial flow, is a serious condition which ultimately will lead to permanent irreversible myocardial cell damage (myocardial infarction) .
- Myocardial infarction is responsible for 25023 deaths during 1992 in Sweden, as mentioned above.
- the development of myocardial infarction is strongly dependent of ischemic duration, thus a complete obstruction of arterial blood flow to a defined area (area at risk) starts to produce irreversible damage within 10 to 15 minutes, after 60 minutes 80-90% of the area at risk comprises of myocardial infarction.
- the detection of myocardial ischemia is today mainly dependent of alterations of the electrocardiogram (ECG) , however with an approximate sensivity and specificity of only 70%.
- ECG electrocardiogram
- Other means by which a myocardial infarction can be detected comprise of analyzing enzymes and other substances in venous blood, released from irreversible damaged myocardial cells.
- the disadvantages of these analyses are the duration time for the analysis itself, often several hours, and the time lag (3-6hrs) between the irreversible myocardial damage and the emergent of the specific markers.
- Ischemia in a heart produces an immediate shift in metabolism from aerobic to anaerobic, which is reflected by for example a rapid transient production of lactate instead of consumption.
- lactate and certain substances related to ischemia such as glutamate, asparate, taurine, hypoxanthine and adenosine are released to the blood compartment with a maximal concentration in venous blood of the heart i.e., contained in the coronary sinus and the thebesian veins, the substances are further quickly dispersed into the main blood stream pumped by the heart, also the half-life of the substances are short due to metabolic consumption of the blood itself and the peripheral tissue, thus a transient detection is possible only in the pulmonary artery and possibly in systemic arteries but not in systemic venous blood.
- substances related to ischemia such as glutamate, asparate, taurine, hypoxanthine and adenosine are released to the blood compartment with a maximal concentration in venous blood of the heart i.e., contained in the coronary sinus and the thebesian veins, the substances are further quickly dispersed into the main blood stream pumped by the heart, also the half-life of the substances are short due to metabolic consumption of
- Microdialysis has been used to monitor the interstitial fluid in various body organs with respect to local metabolic changes, as mentioned above.
- the present invention relates to a method of continuos detection of transient or more long-lasting production or release of substances from the heart related to metabolic changes in a heart and a specially designed microdialysis catheter to be used in the method.
- the method has the advantage compared to the traditional metabolic analysis of markers related to myocardial ischemia, that it is not limited to the analysis of substances with a long life time (e.g. half- life being hours-days) , and requires no sampling of blood and thereby continuos analysis is possible with a short time for analysis.
- the method can indicate ischemic changes in a heart in an early stage prior to development of extended permanent myocardial damage, it will therefore be very useful for the guidance of intervention.
- a disadvantage with conventional blood sampling is that it is limited to momentary situations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Water Supply & Treatment (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- External Artificial Organs (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99909435A EP1061969A2 (en) | 1998-03-11 | 1999-02-24 | A catheter to be inserted into a blood vessel, and a method for detection of substances |
AU28635/99A AU2863599A (en) | 1998-03-11 | 1999-02-24 | A catheter to be inserted into a blood vessel, and a method for detection of substances |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9800791A SE511933C2 (en) | 1998-03-11 | 1998-03-11 | Catheter designed to be inserted into a blood vessel |
SE9800791-7 | 1998-03-11 | ||
SE9804081-9 | 1998-11-26 | ||
SE9804081A SE511932C2 (en) | 1998-03-11 | 1998-11-26 | A method and catheter for detecting substances |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999045982A2 true WO1999045982A2 (en) | 1999-09-16 |
WO1999045982A3 WO1999045982A3 (en) | 1999-11-25 |
Family
ID=26663231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/000259 WO1999045982A2 (en) | 1998-03-11 | 1999-02-24 | A catheter to be inserted into a blood vessel, and a method for detection of substances |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1061969A2 (en) |
AU (1) | AU2863599A (en) |
SE (1) | SE511932C2 (en) |
WO (1) | WO1999045982A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE20021360U1 (en) * | 2000-12-18 | 2001-03-22 | Mueller Geraetebau Gmbh Dr | Blood analysis device for determining blood constituents |
WO2003003911A2 (en) * | 2001-07-06 | 2003-01-16 | Lukas Schaupp | Measurement of the concentration of substances in living organisms using microdialysis |
DE10247023A1 (en) * | 2002-10-09 | 2004-04-22 | Disetronic Licensing Ag | Micro dialysis probe, as a needle to measure concentration of substances in human/animal tissue fluids, has a needle frame with grooves for the inflow/outflow lines and a penetration point |
WO2006033674A1 (en) * | 2004-05-14 | 2006-03-30 | Organ Recovery Systems, Inc. | Apparatus and method for perfusion and determining the viability of an organ |
WO2007048786A1 (en) * | 2005-10-27 | 2007-05-03 | Cma/Microdialysis Ab | Microdialysis probe |
WO2008059050A2 (en) | 2006-11-17 | 2008-05-22 | Trace Analytics Gmbh | Sample taking device, and sample taking methods |
WO2009095020A1 (en) * | 2008-01-30 | 2009-08-06 | Diramo A/S | A micro-dialysis probe and a method of making the probe |
DE102009001455A1 (en) | 2009-03-10 | 2010-09-16 | Trace Analytics Gmbh | Sampling device for attachment to e.g. hollow needle for sampling blood of human in chemical industry, has probe chamber formed as inner recess, and separation membrane surrounding inner recess for penetrating analytes from probe chamber |
US8535537B2 (en) | 2006-10-19 | 2013-09-17 | Joanneum Research Forschungsgesellschaft Mbh | Devices for and methods of monitoring a parameter of a fluidic sample by microdialysis |
US8765364B2 (en) | 2007-05-18 | 2014-07-01 | Lifeline Scientific, Inc. | Ex vivo methods for validating substance testing with human organs and/or tissues |
US8771930B2 (en) | 2007-05-18 | 2014-07-08 | Lifeline Scientific, Inc. | Ex vivo methods for testing toxicity of substances using donated human organs or tissues |
US10022081B2 (en) | 2009-03-10 | 2018-07-17 | Trace Analytics, Gmbh | Sampling device and sampling method |
US10176887B1 (en) | 2005-11-14 | 2019-01-08 | Organ Recovery Systems, Inc. | Ex vivo methods for drug discovery, development and testing |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8602990B2 (en) | 2008-12-09 | 2013-12-10 | Md Biomedical Ab | Method and device for microdialysis sampling |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4340615A (en) * | 1979-06-07 | 1982-07-20 | The Medishield Corporation Limited | Apparatus for analysis of absorbed gases |
US4694832A (en) * | 1982-12-01 | 1987-09-22 | Ungerstedt Carl U | Dialysis probe |
US5097834A (en) * | 1987-02-02 | 1992-03-24 | Avl Ag | Process for determining parameters of interest in living organisms |
US5690103A (en) * | 1996-06-20 | 1997-11-25 | Groth; Torgny Lars | Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61206459A (en) * | 1985-03-11 | 1986-09-12 | 株式会社日立製作所 | Catheter |
-
1998
- 1998-11-26 SE SE9804081A patent/SE511932C2/en unknown
-
1999
- 1999-02-24 AU AU28635/99A patent/AU2863599A/en not_active Abandoned
- 1999-02-24 EP EP99909435A patent/EP1061969A2/en not_active Withdrawn
- 1999-02-24 WO PCT/SE1999/000259 patent/WO1999045982A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4340615A (en) * | 1979-06-07 | 1982-07-20 | The Medishield Corporation Limited | Apparatus for analysis of absorbed gases |
US4694832A (en) * | 1982-12-01 | 1987-09-22 | Ungerstedt Carl U | Dialysis probe |
US5097834A (en) * | 1987-02-02 | 1992-03-24 | Avl Ag | Process for determining parameters of interest in living organisms |
US5690103A (en) * | 1996-06-20 | 1997-11-25 | Groth; Torgny Lars | Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 8643, Derwent Publications Ltd., London, GB; AN 86-282132, XP002921010 & JP 61 206 459 A (HITACHI LTD) 12 September 1986 * |
LäKARTIDNINGEN, BERTIL LINDAHL et al: "Biokemiska Markörer Kan Ge Tidig av Myokardskada", Vol. 95, No. 26-27, 1998, pages 3034 - 3038, XP002919909 * |
PATENT ABSTRACTS OF JAPAN & JP 61 206 459 A (HITACHI LTD) 12 September 1986 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE20021360U1 (en) * | 2000-12-18 | 2001-03-22 | Mueller Geraetebau Gmbh Dr | Blood analysis device for determining blood constituents |
WO2003003911A2 (en) * | 2001-07-06 | 2003-01-16 | Lukas Schaupp | Measurement of the concentration of substances in living organisms using microdialysis |
WO2003003911A3 (en) * | 2001-07-06 | 2003-05-01 | Lukas Schaupp | Measurement of the concentration of substances in living organisms using microdialysis |
US7022071B2 (en) | 2001-07-06 | 2006-04-04 | Lukas Schaupp | Method for measuring the concentration of substances in living organisms using microdialysis and a device for carrying out said method |
DE10247023A1 (en) * | 2002-10-09 | 2004-04-22 | Disetronic Licensing Ag | Micro dialysis probe, as a needle to measure concentration of substances in human/animal tissue fluids, has a needle frame with grooves for the inflow/outflow lines and a penetration point |
DE10247023B4 (en) * | 2002-10-09 | 2006-07-20 | Disetronic Licensing Ag | Microdialysis probe and method for its production |
WO2006033674A1 (en) * | 2004-05-14 | 2006-03-30 | Organ Recovery Systems, Inc. | Apparatus and method for perfusion and determining the viability of an organ |
US8741555B2 (en) | 2004-05-14 | 2014-06-03 | Organ Recovery Systems, Inc. | Apparatus and method for perfusion and determining the viability of an organ |
WO2007048786A1 (en) * | 2005-10-27 | 2007-05-03 | Cma/Microdialysis Ab | Microdialysis probe |
US10176887B1 (en) | 2005-11-14 | 2019-01-08 | Organ Recovery Systems, Inc. | Ex vivo methods for drug discovery, development and testing |
US8535537B2 (en) | 2006-10-19 | 2013-09-17 | Joanneum Research Forschungsgesellschaft Mbh | Devices for and methods of monitoring a parameter of a fluidic sample by microdialysis |
DE202007019544U1 (en) | 2006-11-17 | 2013-06-18 | Trace Analytics Gmbh | sampling device |
WO2008059050A2 (en) | 2006-11-17 | 2008-05-22 | Trace Analytics Gmbh | Sample taking device, and sample taking methods |
US8765364B2 (en) | 2007-05-18 | 2014-07-01 | Lifeline Scientific, Inc. | Ex vivo methods for validating substance testing with human organs and/or tissues |
US8771930B2 (en) | 2007-05-18 | 2014-07-08 | Lifeline Scientific, Inc. | Ex vivo methods for testing toxicity of substances using donated human organs or tissues |
WO2009095020A1 (en) * | 2008-01-30 | 2009-08-06 | Diramo A/S | A micro-dialysis probe and a method of making the probe |
DE102009001455A1 (en) | 2009-03-10 | 2010-09-16 | Trace Analytics Gmbh | Sampling device for attachment to e.g. hollow needle for sampling blood of human in chemical industry, has probe chamber formed as inner recess, and separation membrane surrounding inner recess for penetrating analytes from probe chamber |
US10022081B2 (en) | 2009-03-10 | 2018-07-17 | Trace Analytics, Gmbh | Sampling device and sampling method |
DE102009001455B4 (en) | 2009-03-10 | 2021-10-14 | Trace Analytics Gmbh | Sampling device and method |
Also Published As
Publication number | Publication date |
---|---|
SE9804081L (en) | 1999-09-12 |
WO1999045982A3 (en) | 1999-11-25 |
SE9804081D0 (en) | 1998-11-26 |
EP1061969A2 (en) | 2000-12-27 |
SE511932C2 (en) | 1999-12-20 |
AU2863599A (en) | 1999-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6264627B1 (en) | Catheter to be inserted into a blood vessel, and a method for detection of substances and metabolic changes in a heart | |
EP1061969A2 (en) | A catheter to be inserted into a blood vessel, and a method for detection of substances | |
JP3001992B2 (en) | In vivo blood component monitoring system | |
US5389217A (en) | Measurement of bladder oxygen | |
EP0536808B1 (en) | Intravascular blood parameter measurement system | |
US3866599A (en) | Fiberoptic catheter | |
CA1229020A (en) | Medical catheter | |
US9649037B2 (en) | Method and apparatus for hemodynamic monitoring using combined blood flow and blood pressure measurement | |
US5441481A (en) | Microdialysis probes and methods of use | |
CA1332078C (en) | Blood parameter measurement system | |
US8086323B2 (en) | Implantable multi-parameter sensing system and method | |
US8229546B2 (en) | Microdialysis catheter and a method of making a microdialysis catheter | |
Rolfe | In vivo chemical sensors for intensive-care monitoring | |
WO2020123791A1 (en) | Multipurpose wearable endovascular apparatus | |
US8602990B2 (en) | Method and device for microdialysis sampling | |
WO2009142599A1 (en) | Device for detecting oxygen depletion in fetuses during childbirth | |
WO2007048786A1 (en) | Microdialysis probe | |
Weiss et al. | Evaluation of an improved blood-conserving POCT sampling system | |
US20240066199A1 (en) | Guided blood filtration therapy, systems, and methods | |
US20230329601A1 (en) | Catheter including a sensor configured to sense a biomarker | |
CA1335709C (en) | Hollow viscus and solid organ tonometry | |
CA3166340A1 (en) | Membrane sealing for a physiological sensor | |
WO2020148577A1 (en) | Continuous equilibrium-based diagnostic and therapeutic system | |
Rolfe | Experience with invasive and non‐invasive sensors for anaesthesia | |
Foëx | Continuous In Vivo Measurement of Gas Tension in Blood and in Tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999909435 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999909435 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999909435 Country of ref document: EP |